CD135 (FLT3), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD135 (FLT3), Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD135 (FLT3), Human |
| Clone | BV10A4H2 |
| Host Species | Mouse |
| Reactive Species | human |
| Isotype | IgG1κ |
| Format | biotin conjugate |
| Size | 100 tests in 1 mL |
| Concentration | 1:11 |
| Applications | Flow cytometry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD135 (FLT3) Antibody, anti-human, Biotin. Clone BV10A4H2 recognizes the human CD135 antigen, a single-pass type I membrane protein also known as Fms-like tyrosine kinase receptor 3 (FLT3) or fetal liver kinase-2 (FLK-2). CD135 belongs to the same family as FMS, KIT, and the two genes encoding PDGFRα and β. CD135 is normally expressed by hematopoietic stem and progenitor cells and expression is lost as hematopoietic cells differentiate. Although CD135 expression is usually lost upon HSC differentiation, dendritic cells are an exception, as mature DCs display persistent FLT3 expression. CD135 is also expressed on malignant hematopoietic cells including AML, ALL, and CML-BC. All hematopoietic cells develop from CD135 negative hematopoietic stem cells through CD135 positive progenitor cells. In synergy with other growth factors like G-CSF, GM-CSF, SCF, and IL-3, ligation of CD135 with FLT3 ligand promotes the differentiation, proliferation, and survival of hematopoietic progenitor cells and of dendritic cells. As a result early B cell lineage differentiation as well as expansion of monocytes and immature dendritic cells are stimulated. |
| Immunogen | n/a |
| Other Names | FLT3, FLK-2, STK-1 |
| Gene, Accession # | Gene ID: 2322 |
| Catalog # | 130-106-280 |
| Price | $264 |
| Order / More Info | CD135 (FLT3), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Small, D. et al. (1994) STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc. Natl. Acad. Sci. U.S.A. 91 (2): 459-463. | Leung, A. Y. et al. (2013) FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia. Leukemia 27 (2): 260-268. | Rosnet, O. et al. (1996) Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 10 (2): 238-248. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies